Study of Tremelimumab and Durvalumab (MEDI4736) (T300+D) in Advanced Hepatocellular Carcinomas With Child-Pugh-B Cirrhosis

NCT06526104 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

32

Enrollment

OTHER

Sponsor class

Conditions

Hepatocellular Carcinoma
Cirrhosis, Liver

Interventions

DRUG: Tremelimumab
DRUG: Durvalumab

Sponsor

The University of Texas Health Science Center at San Antonio

Collaborators

[object Object]